This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Procedure costs: electrocardiograms (ECGs), blood draws, IV infusions, radiology, ophthalmology, and other specialized assessments. Technology costs: fees for site-owned platforms such as a clinicaltrial management system (CTMS), eRegulatory management system, eSource platform, or any other specialized digital solution used during the trial.
Institutional review boards (IRBs) play a crucial role in the ever-evolving field of clinical research. Innovations in fields such as immunotherapy, cancer and chronic diseases owe their existence to clinicaltrials, which judiciously test and evaluate safety and efficacy.
Similar to the FDA, the EMA evaluates radiopharmaceuticals for safety, efficacy, quality, and GMP regulation compliance before granting marketing authorization. International Commission on Radiological Protection (ICRP) The ICRP provides recommendations and guidance on radiation protection standards for occupational and public exposure.
The Principal Investigator (PI) of any study, be it drug or device, has many responsibilities, including ensuring regulatory compliance, overseeing the conduct of the study, and safeguarding the well-being of study participants.
With many clinical research sites facing study start-up delays and backlogs, performing a coverage analysis efficiently and thoroughly is critical to the study start-up process. But why is the coverage analysis process so vital for clinicaltrials and how can research sites do it more effectively?
HistoSonics announced the results of its pivotal #HOPE4LIVER trials, showcasing the Edison Histotripsy System’s effectiveness in non-invasively destroying liver tumors. The trials, published in Radiology , involved 44 patients and 49 tumors — ranging from primary liver cancers to metastatic tumors.
On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022.
Medtronic’s proactive stance towards R&D is evident from the over 230 clinicaltrials it conducted and the more than 200 regulatory approvals it received in the US, Europe, Japan and China in the 2022 fiscal year. The company reported an investment of $2.7
In recent years, the landscape of women’s health clinicaltrials has begun to shift. Read on to learn more about the historical challenges, recent advancements, clinical considerations, and the future of women’s health clinicaltrials, as detailed by Medpace’s women’s health experts.
Overall, patient compliance for PROs was greater than 90 percent. Across clinicaltrials (MONARCH 1, MONARCH 2, MONARCH 3), 3.3% Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Expectedly, patient-reported diarrhea was more common in patients receiving Verzenio plus ET.
Procedure costs: electrocardiograms (ECGs), blood draws, IV infusions, radiology, ophthalmology, and other specialized assessments. Technology costs: fees for site-owned platforms such as a clinicaltrial management system (CTMS), eRegulatory management system, eSource platform, or any other specialized digital solution used during the trial.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content